Is Celcuity (CELC) Undervalued After Its Removal From Major Russell Indices?

Celcuity (CELC) was recently removed from several Russell indices, including value, growth, small cap and microcap benchmarks. This administrative change can reshape trading flows as index funds and ETFs rebalance holdings.

See our latest analysis for Celcuity.

Despite being removed from multiple Russell indices, Celcuity’s share price has recently shown strong momentum, with a 22.28% 1 month share price return and a 7.36% year to date share price return, while its 1 year total shareholder return is very large.

If you are looking beyond Celcuity and want to see what else is moving in high growth areas of the market, now could be a good time to check out 40 healthcare AI stocks.

With Celcuity trading at $107.95, an intrinsic value estimate that implies a large discount and analyst targets that sit higher, the key question is whether the stock still offers mispricing or if the market is already assuming strong future growth.

Most Popular Narrative: 33% Undervalued

Celcuity’s most followed narrative sets a fair value of $161.09 against the last close at $107.95, framing a sizeable gap that rests on ambitious growth and profitability expectations.

Celcuity currently has no revenue. Analysts are forecasting revenue to reach $817.9 million by June 2029.

As a pre-revenue company, Analysts expect Celcuity to achieve a profit margin of 32.7% in 3 years time.

Read the complete narrative.

Want to see how a zero revenue biotech gets priced for sizeable earnings and premium multiples, while assuming rapidly expanding margins and rising scale, without any room for hesitation?

Result: Fair Value of $161.09 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Celcuity’s story can change quickly if key gedatolisib trials disappoint or regulators delay approvals. This would prolong losses and challenge current valuation assumptions.

Find out about the key risks to this Celcuity narrative.

Another View on Celcuity’s Valuation

While the main Celcuity narrative leans on future earnings and high implied P/E multiples, our DCF model offers a different perspective. On this approach, Celcuity at $107.95 trades at an 88.5% discount to an estimated future cash flow value of $936.42, which still assumes a lot needs to go right. How comfortable are you with that gap?

To see how this cash flow based view is built and what needs to happen for the numbers to hold up, take a closer look at the SWS DCF model for Celcuity, starting with Look into how the SWS DCF model arrives at its fair value.

Next Steps

With such a mixed picture around Celcuity, now is the moment to move quickly, review the full data set and form your own stance, starting with 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Celcuity?

If Celcuity has your attention, do not stop there, use this moment to widen your watchlist before other investors crowd into the next set of opportunities.

• Spot potential high growth early and scan through 20 elite penny stocks with strong financials that combine smaller market sizes with stronger fundamentals than many expect.
• Zero in on value opportunities by checking stocks in the 44 high quality undervalued stocks that pair quality metrics with prices that lag underlying fundamentals.
• Prioritise resilience and capital strength by reviewing companies in the solid balance sheet and fundamentals stocks screener (47 results) where cleaner balance sheets support more flexibility through different market conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com